


113/04/2957




सत्यमेव जयते



GOVERNMENT OF INDIA
MINISTRY OF COMMERCE & INDUSTRY
PATENT OFFICE, DELHI BRANCH
W - 5, WEST PATEL NAGAR
NEW DELHI - 110 008.

I, the undersigned being an officer duly authorized in accordance with the provision of the Patent Act, 1970 hereby certify that annexed hereto is the true copy of the Application, Complete Specification and Drawing Sheets filed in connection with Application for Patent No. 1144/Del/2003 dated 12th September 2003.

Witness my hand this 16th day of November 2004.



(S.K. PANGASA)

Assistant Controller of Patents & Designs

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

THE PATENTS ACT, 1970
(39 of 1970)

APPLICATION FOR GRANT OF A PATENT

(See Sections 5(2), 7, 54 and 135; and rule 39)

We, **RANBAXY LABORATORIES LIMITED**, a Company incorporated under the Companies Act, 1956, Corporate Office at 19, Nehru Place, New Delhi - 110 019, India.

hereby declare -

- (a) that we are in possession of an invention titled "**PROCESS FOR PRODUCTION OF CRYSTALLINE FORMS OF OXETANONE DERIVATIVE**"
- (b) that the Complete Specification relating to this invention is filed with this application.
- (c) that there is no lawful ground of objection to the grant of a patent to us.

3. Further declare that the inventors for the said invention are

- a. YATENDRA KUMAR 
- b. MOHAN PRASAD 
- c. KESHAV DEO 
- d. ANAND PANDEY 
- e. KILOL PATEL 
- f. SEEMA KANWAR 

of Ranbaxy Laboratories Limited, Plot No. 20, Sector-18, Udyog Vihar Industrial Area, Gurgaon – 122001 (Haryana), India, all Indian Nationals

We claim the priority from the application(s) filed in convention countries, particulars of which are as follows: **NOT APPLICABLE**

5. We state that the said invention is an improvement in or modification of the invention, the particulars of which are as follows and of which we are the applicant: **NOT APPLICABLE**

6. We state that the application is divided out of our application, the particulars of which are given below and pray that this application deemed to have been filed on Under section 16 of the Act. **NOT APPLICABLE**

7. That we are the assignee or legal representative of the above named
Subcontractor.

⁸ That our address of 20th January 1863.

service in India is as follows:


DR. B. VIJAYARAGHAVAN
Associate Director – Intellectual Property

Ranbaxy Laboratories Limited
Plot No.20, Sector - 18, Udyog Vihar Industrial Area,
Gurgaon - 122001 (Haryana), INDIA

9. Following declaration was given by the inventors or applicants in the convention country:
We, YATENDRA KUMAR, MOHAN PRASAD, KESHAV DEO, ANAND PANDEY, KILOL PATEL, SEEMA KANWAR of Ranbaxy Laboratories Limited, Plot No. 20, Sector - 18, Udyog Vihar Industrial Area, Gurgaon-122001 (Haryana), India, all Indian Nationals, the true and first inventors for this invention or applicant in the convention country declare that the applicant herein, **Ranbaxy Laboratories Limited**, Corporate Office at 19, Nehru Place, New Delhi - 110 019, India, is our assignee or legal representatives.

a.

(YATENDRA KUMAR)



b.

(MOHAN PRASAD)



c.

(KESHAV DEO)



d.

(ANAND PANDEY)



e.

(KILOL PATEL)



f.

(SEEMA KANWAR)

10. That to the best of our knowledge, information and belief the fact and matters stated herein are correct and that there is no lawful ground of objection to the grant of patent to us on this application.


11. Followings are the attachment with the application:

- a. Complete Specification (3 copies)
- b. Drawings (3 copies)
- c. Priority document(s)
- d. Statement and Undertaking on FORM - 3
- e. Power of Authority (Not required)
- f. Fee Rs.3,000/- (Rupees Three Thousand only..) in cheque bearing No.
dated : drawn on

We request that a patent may be granted to us for the said invention.

Dated this 12TH day of September, 2003.

For Ranbaxy Laboratories Limited


SUSHIL KUMAR PATAWARI
Company Secretary

1144 DEK 03

FORM 2

100 FORM 2003

The Patents Act, 1970
(39 of 1970)

COMPLETE SPECIFICATION
(See Section 10)

**PROCESS FOR PRODUCTION OF
CRYSTALLINE FORMS OF OXETANONE
DERIVATIVE**

RANBAXY LABORATORIES LIMITED
19, NEHRU PLACE, NEW DELHI - 110019

A Company incorporated under the Companies Act, 1956.

The following specification particularly describes and ascertains the nature of this invention and the manner in which it is to be performed:

A process for preparing a crystalline form II of orlistat, which is tetrahydrolipstatin, is provided. Further a process for preparing crystalline form I of orlistat from crystalline form II of orlistat, is provided.

Orlistat is a useful pancreatic lipase-inhibiting agents and can be used for the prevention and treatment of obesity and hyperlipaemia. Chemically, It is N-formyl-L-leucine[2S-[2alpha(R*),3 beta]]-1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester and is known from US patent US 4,598,089, in which the product is isolated as a waxy material.

Purification of orlistat by chromatographic method using toluene and ethyl acetate has been reported in several references such as US 4,983,746; *Helv. Chim. Acta.* 1987, 70, 1412; *J. Org. Chem.*, 1988, 53, 1218 and *J. Org. Chem.*, 1993, 58,7768.

J. Chem. Soc. Perkin. Trans. I, 1998, 17, 2679 reports the use of hexane and ethyl acetate for chromatographic purification of orlistat to obtain the product as an amorphous solid.

Further, US 6,156,911; *Tetrahedron letters*, 1989, 30, 1833; *J. Org. Chem.*, 1991, 56, 4714 and *Helv. Chim. Acta.* 1987, 70, 1412 disclose a crystalline form of orlistat, obtained by recrystallization with hydrocarbons such as hexane, pentane and heptane, and characterized it by melting point and infrared spectroscopy. For convenience this crystalline form is herein after called as form I.

Another crystalline form of orlistat, with unique X-ray diffraction pattern, is marketed by Roche as Xenical capsules but surprisingly, has not been reported anywhere. It is herein after called as form II.

The characteristic XRD, IR spectra and DSC graph of form I are given as figure 1, 2 and 3 respectively, as shown in the accompanied drawings. The characteristic XRD, IR spectra and DSC graph of form II are given as figure 4, 5 and 6 respectively, as shown in the accompanied drawings.

A process for preparing a crystalline form II of orlistat comprising crystallizing orlistat from diisopropyl ether is provided.

Further, a process for preparing the crystalline form I of orlistat comprising heating form II of orlistat till it melts and allowing it to cool, is provided.

The starting orlistat, to be used in the preparation of crystalline form II of orlistat, may be obtained as a solution directly from a reaction mixture in which orlistat is formed and used as such without isolation. Alternatively, form I, amorphous or waxy form of orlistat may be used.

Orlistat can be obtained by methods known in the art including US 4,598,089; US 4,983,746; US 6,156,911; US 5,412,110; US 2002110873; *Helv. Chim. Acta.* 1987, 70, 1412; *J. Org. Chem.* 1988, 53, 1218; *J. Org. Chem.* 1993, 58, 7768; *J. Chem. Soc. Perkin. Trans. I*, 1998, 17, 2679; *Tetrahedron letters*, 1989, 30, 1833; *J. Org. Chem.* 1991, 56, 4714 and *Chem. Commun.* 1999, 17, 1743.

In general, the crystallization is carried out by dissolving orlistat in diisopropyl ether, optionally concentrating the solution obtained, and cooling the solution till a precipitate is obtained, stirring at the same temperature till complete precipitation followed by filtration or centrifugation and drying. Precipitation may also be achieved without stirring.

The volume of diisopropyl ether to dissolve orlistat may be 2 to 10 volume by weight of orlistat.

Orlistat and diisopropyl ether may be stirred at room temperature or higher temperatures up to reflux temperature to get a clear solution.

The obtained solution may be cooled from about 5 to about -20°C to precipitate form II of orlistat.

The precipitate is filtered at the same temperature and dried at room temperature under reduced pressure.

The crystalline form II of orlistat is converted to crystalline form I of orlistat by heating to 40 to 45°C to get a melted syrup. The melted orlistat is allowed to cool at room temperature under reduced pressure till a good crystalline solid is obtained.

In the following section embodiments are described by way of examples to illustrate the processes of the invention. However, these are not intended in any way to limit the scope of the present invention. Several variants of these examples would be evident to persons ordinarily skilled in the art.

Example-1

Preparation of orlistat form II

Orlistat form I (2.0 g) was dissolved in diisopropyl ether (10.0 ml) and stirred at room temperature to get clear solution. The reaction mixture was cooled to 0 to -5°C and the product was precipitated slowly with stirring. The product was filtered and washed with diisopropyl ether. It was then dried at room temperature under vacuum to obtain white crystals of orlistat.

Yield: 1.7 g

XRD, IR spectra and DSC graph were similar to those shown by Fig. 4.5 and 6 respectively, as shown in the accompanied drawings.

Example-2

Preparation of orlistat form I from orlistat form II

2.0 g of orlistat form II was taken and the temperature was raised to 42°C using a water bath to form melted syrup. The syrupy material was dried under reduced pressure to obtain white crystalline orlistat.

XRD, IR spectra and DSC graph were similar to those shown by Fig. 1, 2 and 3 respectively, as shown in the accompanied drawings.

WE CLAIM:

1. A process for preparing crystalline form II of orlistat, comprising crystallizing orlistat from diisopropyl ether.
2. The process according to claim 1, wherein orlistat, obtained as a solution directly from a reaction mixture, is used.
3. The process according to claim 1, wherein amorphous form of orlistat is used.
4. The process according to claim 1, wherein form I of orlistat is used.
5. The process according to claim 1, wherein orlistat is dissolved in diisopropyl ether.
6. The process according to claim 5, wherein the volume of diisopropyl ether is 2 to 10 volume by weight of orlistat.
7. The process according to claim 5, wherein orlistat and diisopropyl ether are stirred at room temperature to get clear solution.
8. The process according to claim 5, wherein orlistat and diisopropyl ether are refluxed to get clear solution.
9. The process according to claim 5, wherein the solution of orlistat in diisopropyl ether is cooled from about 5 to about -20°C to obtain crystals of form II.
10. A process for preparing crystalline form I of orlistat, comprising heating form II of orlistat till it melts and allowing it to cool.
11. A process for the preparation of crystalline form II of orlistat as herein described and illustrated by the examples herein.

Dated 11TH day of September, 2003.

For Ranbaxy Laboratories Limited


(Sushil Kumar Patawari)
Company Secretary

11-11-1 DEX 07

11-11-1 2003


ABSTRACT

PROCESS FOR PRODUCTION OF CRYSTALLINE FORMS OF OXETANONE DERIVATIVE

A process for preparing crystalline form II of orlistat, is provided. Further a process for preparing the crystalline form I of orlistat from crystalline form II of orlistat, is provided.

11-11-1
JMP


FIGURE 1



For Ranbaxy Laboratories Limited
 (Sushil Kumar Patawari)
 Company Secretary


1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006
 1007
 1008
 1009
 10010
 10011
 10012
 10013
 10014
 10015
 10016
 10017
 10018
 10019
 10020
 10021
 10022
 10023
 10024
 10025
 10026
 10027
 10028
 10029
 10030
 10031
 10032
 10033
 10034
 10035
 10036
 10037
 10038
 10039
 10040
 10041
 10042
 10043
 10044
 10045
 10046
 10047
 10048
 10049
 10050
 10051
 10052
 10053
 10054
 10055
 10056
 10057
 10058
 10059
 10060
 10061
 10062
 10063
 10064
 10065
 10066
 10067
 10068
 10069
 10070
 10071
 10072
 10073
 10074
 10075
 10076
 10077
 10078
 10079
 10080
 10081
 10082
 10083
 10084
 10085
 10086
 10087
 10088
 10089
 10090
 10091
 10092
 10093
 10094
 10095
 10096
 10097
 10098
 10099
 100100
 100101
 100102
 100103
 100104
 100105
 100106
 100107
 100108
 100109
 100110
 100111
 100112
 100113
 100114
 100115
 100116
 100117
 100118
 100119
 100120
 100121
 100122
 100123
 100124
 100125
 100126
 100127
 100128
 100129
 100130
 100131
 100132
 100133
 100134
 100135
 100136
 100137
 100138
 100139
 100140
 100141
 100142
 100143
 100144
 100145
 100146
 100147
 100148
 100149
 100150
 100151
 100152
 100153
 100154
 100155
 100156
 100157
 100158
 100159
 100160
 100161
 100162
 100163
 100164
 100165
 100166
 100167
 100168
 100169
 100170
 100171
 100172
 100173
 100174
 100175
 100176
 100177
 100178
 100179
 100180
 100181
 100182
 100183
 100184
 100185
 100186
 100187
 100188
 100189
 100190
 100191
 100192
 100193
 100194
 100195
 100196
 100197
 100198
 100199
 100200
 100201
 100202
 100203
 100204
 100205
 100206
 100207
 100208
 100209
 100210
 100211
 100212
 100213
 100214
 100215
 100216
 100217
 100218
 100219
 100220
 100221
 100222
 100223
 100224
 100225
 100226
 100227
 100228
 100229
 100230
 100231
 100232
 100233
 100234
 100235
 100236
 100237
 100238
 100239
 100240
 100241
 100242
 100243
 100244
 100245
 100246
 100247
 100248
 100249
 100250
 100251
 100252
 100253
 100254
 100255
 100256
 100257
 100258
 100259
 100260
 100261
 100262
 100263
 100264
 100265
 100266
 100267
 100268
 100269
 100270
 100271
 100272
 100273
 100274
 100275
 100276
 100277
 100278
 100279
 100280
 100281
 100282
 100283
 100284
 100285
 100286
 100287
 100288
 100289
 100290
 100291
 100292
 100293
 100294
 100295
 100296
 100297
 100298
 100299
 100300
 100301
 100302
 100303
 100304
 100305
 100306
 100307
 100308
 100309
 100310
 100311
 100312
 100313
 100314
 100315
 100316
 100317
 100318
 100319
 100320
 100321
 100322
 100323
 100324
 100325
 100326
 100327
 100328
 100329
 100330
 100331
 100332
 100333
 100334
 100335
 100336
 100337

FIGURE - II



For Ranbaxy Laboratories Limited
[Signature]
Rashil Kumar Patawari
(Company Secretary)


FIGURE III



DA
100 °C
100 min
For Ranbaxy Laboratories Limited

(Sushil Kumar Patawari)
Company Secretary

FIGURE - IV




For Ranbaxy Laboratories Limited

Ashish Kumar Patawari
Company Secretary


Shashi Kumar Patawari
Company Secretary

FIGURE V



For Ranbaxy Laboratories Limited
Sushil Kumar Patawari
Company Secretary

FIGURE - VI



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.